Hyperhomocysteinemia and thrombosis

Lipids

Volumn 36, Issue SUPPL., 2001, Pages

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSELS; BODY FLUIDS; CARDIOVASCULAR SYSTEM; DISEASES; PATIENT MONITORING; VITAMINS;

CORONARY ARTERY DISEASES;

AMINO ACIDS;

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS;

EID: 0035698452     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-001-0677-9     Document Type: Conference Paper

References (197)

1. Methionine metabolism in mammals
2. 3) methionine kinetics in humans: Methionine conservation and cysteine sparing
3. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status
4. Plasma Homocysteine and Menopausal Status
5. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study
6. Plasma total homocysteine in healthy subjects: Sex-specific relation with biological traits
7. Serum total homocysteine concentrations in the third national health and nutrition examination survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations
8. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population
9. Coffee consumption and plasma total homocysteine: The Hordaland homocysteine study
10. Hyperhomocysteinemia in chronic alcoholism: Correlation with folate. Vitamin B-12 and vitamin B-6 status
11. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland homocysteine study
12. Vegetarians and cardiovascular risk factors: Hemostasis, inflammatory markers, and plasma homocysteine
13. The effect of diet on plasma homocysteine concentrations in healthy male subjects
14. Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: Ethnic and sex differences in Cobalamin and metabolite abnormalities
15. Distribution of and factors associated with serum homocysteine levels in children: Child and adolescent trial for cardiovascular health
16. Hyperhomocysteinemia, atherosclerosis, and thrombosis
17. Newborn screening for homocystinuria: Irish and world experience
18. Disorders of transulfuration
19. Molecular genetics of methylenetetrahydrofolate reductase deficiency
20. 12 utilization
21. Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis
22. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase
23. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
24. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in U.S. physicians
25. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (>40 μmol/liter). The Hordaland homocysteine study
26. Critical points for determining moderate hyperhomocyst(e)inaemia
27. A second mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects?
28. Metabolic evidence that deficiencies of vitamin B-12 (Cobalamin), folate, and vitamin B-6 occur commonly in elderly people
29. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis
30. Trimethoprim and fasting plasma homocysteine
31. Homocysteine and vascular disease
32. The effect of a subnormal vitamin B-6 status on homocysteine metabolism
33. Lipid-lowering drugs and homocysteine
34. Lipid-lowering drugs and homocysteine
35. Serum homocysteine increases after therapy with fenofibrate or bezafibrate
36. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women
37. Effects of sex steroids on plasma total homocysteine levels: A study in transsexual males and females
38. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen
39. Tamoxifen reduces plasma homocysteine levels in healthy women
40. Protein-bound homocyst(e)ine in patients with rheumatoid arthritis undergoing D-penicillamine treatment
41. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein (a) levels
42. Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease
43. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum
44. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott Imx analyzer
45. Multicenter study of homocysteine measurement. Performance characteristics of different methods, influence of standards on interlaboratory agreement of results
46. Comparison of plasma total homocysteine measurements in 14 laboratories: An international study
47. The detection of heterozygotes for homocystinuria by oral loading with L-methionine
48. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts
49. High prevalence of hyperhomocyst(e)inemia in patients with Juvenile Venous thrombosis
50. Prevalence of moderate hyperhomocysteinemia in patients with early-onset Venous and arterial occlusive disease
51. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
52. Plasma homocystine as a risk factor for vascular disease. The European concerted action project
53. Validation of abbreviated oral methionine-loading test
54. Comparison between the 2-hour and the 4-hour methionine loading test for the identification of subjects with methionine intolerance
55. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by s-adenosylmethionine of the remethylation and transsulfuration of homocysteine
56. Vitamin B-6 deficiency vs. folate deficiency: Comparison of responses to methionine loading in rats
57. A common mutation in the methylene-tetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (Factor V:Q506)
58. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine
59. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation
60. Is the oral methionine loading test insensitive to the remethylation pathway of homocysteine?
61. Vascular pathology of homocysteinemia: Implications for the pathogenesis of atherosclerosis
62. Homocysteine and cardiovascular disease
63. The Pathogenesis of coronary artery disease. A possible role for methionine metabolism
64. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
65. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease
66. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease
67. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine. Related genetic polymorphisms, and B vitamins. The atherosclerosis risk in communities (ARIC) study
68. Carotid Artery Intimal-Medial Wall Thickening and Plasma Homocyst(e)ine in Asymptomatic Adults. The Atherosclerosis in Communities (ARIC) Study
69. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam study
70. Correlation between plasma homocyst(e)ine and aortic atherosclerosis
71. Plasma total homocysteine, B vitamins and risk of coronary atherosclerosis, arterioscler
72. Effects of age, lipoproteins, and hemostatic parameters on the role of homocystinemia as a cardiovascular risk factor in men
73. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease
74. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease
75. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective finnish population based study
76. Serum homocysteine and the five year risk of cardiovascular diseases, cancer and cognitive impairment in elderly men
77. Serum total homocysteine and coronary heart disease
78. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians
79. 6 and risk of myocardial infarction in U.S. physicians
80. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery
81. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke
82. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
83. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial
84. Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention
85. Homocysteine and ischaemic heart disease in the Caerphilly Cohort
86. Serum total homocysteine and coronary heart disease: Prospective study in middle aged men
87. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men. A 10-year follow-up
88. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. The Rotterdam study
89. Nonfasting Plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham study
90. Homocysteine and risk of cardiovascular disease among postmenopausal women
91. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women
92. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem
93. Plasma homocysteine levels and mortality in patients with coronary artery disease
94. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
95. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in endstage renal disease and is closely linked to plasma folate and pyridoxine concentrations
96. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
97. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
98. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
99. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria
100. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes. 5-Year follow-up of the Hoorn study
101. C677T (Thermolabile Alanine/Valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): Its frequency and impact on plasma homocysteine concentration in different European populations
102. Plasma homocysteine and cardiovascular disease mortality
103. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease
104. A study of cardiovascular risk in heterozygotes for homocystinuria
105. Evaluation of the presence of premature atherosclerosis in adults with heterozygosity for cystathionine-beta-synthase deficiency
106. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease
107. Hyperhomocysteinemia: An independent risk factor for vascular disease
108. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease
109. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease
110. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease
111. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors for spontaneous tschemic stroke in childhood
112. High prevalence of a mutation in the cystathionine β-synthase gene
113. A 68-bp insertion found in a homocystinuric patient is a common variant and is skipped by alternative splicing of the cystathionine β-synthase mRNA
114. A Common 844ins68 insertion variant in the cystathionine-β-synthase gene
115. Hyper-homocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The perth carotid ultrasound disease assessment study (CUDAS)
116. Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area
117. Plasma homocysteine in venous thromboembolism
118. Elevated total plasma homocysteine, a risk factor for thrombosis: Relation to coagulation and fibrinolytic parameters
119. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?
120. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
121. Hyperhomocysteinemia and deep-vein thrombosis. A case control study
122. Plasma homocysteine levels in patients with deep venous thrombosis
123. Risk factors for primary deep vein thrombosis of the upper extremities
124. Hyperhomocysteinemia and venous thrombosis: A meta-analysis
125. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease
126. Homozygous cystathionine β-synthase deficiency, combined with factor V leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis
127. Coexistence of hereditary homocystinuria and factor V leiden-effect on thrombosis
128. Interrelation of hyperhomocyst(e)inemia, factor V leiden, and risk of future venous thromboembolism
129. Fasting plasma homocysteine levels do not predict the occurrence of deep-vein thrombosis after elective hip replacement surgery
130. Interrelation of hyperhomocyst(e)inemia, factor V leiden, and risk of future venous thromboembolism
131. Hyperhomocysteinemia, is a risk factor of recurrent venous thromboembolism
132. The mutation ALA677VAL in the methylene-tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis
133. Venous thromboembolic disease and the prothrombin, methylenetetrahydrolfolate reductase and factor V genes
134. Thermolabile methylenetetrahydrofolate reductase and factor V leiden in the risk of deep-vein thrombosis
135. No evidence for an increased risk of venous thrombosis in patients with factor V leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate reductase gene
136. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment
137. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV leiden and the prothrombin A20210 mutation
138. The VITA project: C677T mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism
139. Homocysteine, serum folate, mutated methylenetetrahydrofolate reductase (Mthfr) and factor V leiden and the risk of venous thrombosis
140. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G169 1A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels
141. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the nutrition committee
142. Homocysteine and cardiovascular diseases
143. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients
144. High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: A pathogenic link with thromboembolic complications?
145. Abnormal homocysteine metabolism in rheumatoid arthritis
146. Hyperhomocysteinemia in organ transplantation
147. Plasma homocysteine in children with acute lymphoblastic leukemia. Changes during a chemotherapeutic regimen including methotrexate
148. Plasma homocysteine levels in 10 patients with polycythemia
149. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM
150. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease. Especially in non-insulindependent diabetes mellitus: A population-based study
151. Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis
152. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine
153. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator
154. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells
155. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine
156. An Atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells
157. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor
158. Tissue plasminogen activator binding to annexin II tail domain. Direct modulation by homocysteine
159. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
160. Hyperhomocyst(e)inemia and atherothrombosis
161. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase
162. Effects of homocysteine and related compounds on prostacycline production by cultured human vascular endothelial cells
163. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells
164. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells
165. Homocysteine inhibits ecto-ADPase activity of human umbilical vein endothelial cells
166. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
167. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells
168. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells
169. Homocysteine accelerates endothelial cell senescence
170. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia
171. Plasma Levels of activated protein C in healthy subjects and patients with previous venous thromboembolism. Relationship with plasma homocysteine levels
172. A hypercoagulable state in homocystinuria due to homozygous cystathionine-β-synthase deficiency
173. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucolsensitive mechanism
174. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans
175. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans
176. Acute hyperhomocysteinaemia and endothelial dysfunction
177. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults
178. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia, an effect reversible with vitamin C therapy
179. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins
180. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans
181. Effects of methionine-induced hyperhomocysteinemia on endotheliumdependent vasodilation and oxidative status in healthy adults
182. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial
183. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism
184. Vitamins as homocysteine-lowering agents
185. Vitamin requirements for the treatment of hyperhomocysteinemia in humans
186. Vitamin supplementation reduces blood homocysteine levels: A controlled trial in patients with venous thrombosis and healthy volunteers
187. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
188. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: A randomized trial
189. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients
190. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial
191. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease
192. Increased dietary micronutrients decrease serum homocysteine concentrations in patients at high risk of cardiovascular disease
193. The Effect of folic acid fortification on plasma folate and total homocysteine concentrations
194. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women
195. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population
196. What levels of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/L
197. Arterial thromboembolism. Epidemiology